University of California - San Diego Oct 13 2025 Many advanced cancers develop resistance to treatment and become highly aggressive, often leaving patients with limited treatment options. In some cancers, including lung, pancreatic and prostate tumors, a key driver of treatment resistance and metastasis is a protein called integrin αvβ3, which is absent in normal tissues but enriched in aggressive tumors. Previous attempts to target αvβ3 with antibody therapies worked by activating a specific